Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment

<b>Background/Objectives</b>: Multiple sclerosis (MS) is a disease characterized by demyelination and axonal damage of the central nervous system. Despite the observed benefits, highly effective treatment (HET)-based therapy has adverse effects, which include an increased risk of develop...

Full description

Saved in:
Bibliographic Details
Main Authors: Silvia García, Adriana García-Martell, Sandra Quiñones-Aguilar, Sergio Sauri-Suárez, Mario Antonio Téllez González, Guillermo García-Castillo, Juan Antonio Suárez-Cuenca, Christian Gabriel Toledo-Lozano, Paul Mondragón Terán, Sofia Lizeth Alcaraz-Estrada
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/12/12/2737
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850240127907921920
author Silvia García
Adriana García-Martell
Sandra Quiñones-Aguilar
Sergio Sauri-Suárez
Mario Antonio Téllez González
Guillermo García-Castillo
Juan Antonio Suárez-Cuenca
Christian Gabriel Toledo-Lozano
Paul Mondragón Terán
Sofia Lizeth Alcaraz-Estrada
author_facet Silvia García
Adriana García-Martell
Sandra Quiñones-Aguilar
Sergio Sauri-Suárez
Mario Antonio Téllez González
Guillermo García-Castillo
Juan Antonio Suárez-Cuenca
Christian Gabriel Toledo-Lozano
Paul Mondragón Terán
Sofia Lizeth Alcaraz-Estrada
author_sort Silvia García
collection DOAJ
description <b>Background/Objectives</b>: Multiple sclerosis (MS) is a disease characterized by demyelination and axonal damage of the central nervous system. Despite the observed benefits, highly effective treatment (HET)-based therapy has adverse effects, which include an increased risk of developing progressive multifocal leukoencephalopathy (PML). Additionally, the risk grows if the patient has antibodies for the John Cunningham virus (JCV). The appearance of PML is rare, and only one report has been found in Mexico. The objective of this research was to determine and analyze the immunological memory for JCV in a population of Mexican patients with MS under treatment. <b>Methods</b>: All participants underwent a complete medical history and neurological evaluation. Once they signed their informed consent, a blood sample was taken to determine if antibodies against JCV were present in their serum. <b>Results:</b> In total, 121 MS patients were analyzed, and the population consisted of 62.8% women and 37.2% men with an average age of 42.28. The three most common HETs received by the participants were natalizumab (67.76%), followed by teriflunomide and fingolimod. <b>Conclusions</b>: The seropositivity was 62.8%, and in this group, the average duration of disease evolution was 152.33 ± 93.37 months. Natalizumab was the most used HET, and despite this, only a positive association between a positive JCV antibody index with duration of fingolimod and history of depression was found. Also, a positive correlation of the JCV Ab index within the forms of SPMS and PPMS compared to RRMS was observed. No differences were observed between populations, type, and duration of MS.
format Article
id doaj-art-3543fe97b5ea49288967005e7d1d489b
institution OA Journals
issn 2227-9059
language English
publishDate 2024-11-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-3543fe97b5ea49288967005e7d1d489b2025-08-20T02:00:56ZengMDPI AGBiomedicines2227-90592024-11-011212273710.3390/biomedicines12122737Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under TreatmentSilvia García0Adriana García-Martell1Sandra Quiñones-Aguilar2Sergio Sauri-Suárez3Mario Antonio Téllez González4Guillermo García-Castillo5Juan Antonio Suárez-Cuenca6Christian Gabriel Toledo-Lozano7Paul Mondragón Terán8Sofia Lizeth Alcaraz-Estrada9Clinical Research Department, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoClinical Research Department, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoNeurology Department, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoNeurology Department, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoBiomedical Research Division, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoSpecial Testing Laboratory, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoClinical Research Department, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoClinical Research Department, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, MexicoCentro de Investigación en Ciencia Aplicada y Tecnología Avanzada Unidad Morelos, Instituto Polítecnico Nacional, Mexico City 03100, MexicoVirological Analysis and Reference Unit, National Medical Center “20 de Noviembre” Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City 03100, Mexico<b>Background/Objectives</b>: Multiple sclerosis (MS) is a disease characterized by demyelination and axonal damage of the central nervous system. Despite the observed benefits, highly effective treatment (HET)-based therapy has adverse effects, which include an increased risk of developing progressive multifocal leukoencephalopathy (PML). Additionally, the risk grows if the patient has antibodies for the John Cunningham virus (JCV). The appearance of PML is rare, and only one report has been found in Mexico. The objective of this research was to determine and analyze the immunological memory for JCV in a population of Mexican patients with MS under treatment. <b>Methods</b>: All participants underwent a complete medical history and neurological evaluation. Once they signed their informed consent, a blood sample was taken to determine if antibodies against JCV were present in their serum. <b>Results:</b> In total, 121 MS patients were analyzed, and the population consisted of 62.8% women and 37.2% men with an average age of 42.28. The three most common HETs received by the participants were natalizumab (67.76%), followed by teriflunomide and fingolimod. <b>Conclusions</b>: The seropositivity was 62.8%, and in this group, the average duration of disease evolution was 152.33 ± 93.37 months. Natalizumab was the most used HET, and despite this, only a positive association between a positive JCV antibody index with duration of fingolimod and history of depression was found. Also, a positive correlation of the JCV Ab index within the forms of SPMS and PPMS compared to RRMS was observed. No differences were observed between populations, type, and duration of MS.https://www.mdpi.com/2227-9059/12/12/2737multiple sclerosisJCVantibody indexHET
spellingShingle Silvia García
Adriana García-Martell
Sandra Quiñones-Aguilar
Sergio Sauri-Suárez
Mario Antonio Téllez González
Guillermo García-Castillo
Juan Antonio Suárez-Cuenca
Christian Gabriel Toledo-Lozano
Paul Mondragón Terán
Sofia Lizeth Alcaraz-Estrada
Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment
Biomedicines
multiple sclerosis
JCV
antibody index
HET
title Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment
title_full Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment
title_fullStr Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment
title_full_unstemmed Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment
title_short Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment
title_sort analysis of immunological memory for john cunningham virus in a mexican population of patients with multiple sclerosis under treatment
topic multiple sclerosis
JCV
antibody index
HET
url https://www.mdpi.com/2227-9059/12/12/2737
work_keys_str_mv AT silviagarcia analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT adrianagarciamartell analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT sandraquinonesaguilar analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT sergiosaurisuarez analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT marioantoniotellezgonzalez analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT guillermogarciacastillo analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT juanantoniosuarezcuenca analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT christiangabrieltoledolozano analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT paulmondragonteran analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment
AT sofializethalcarazestrada analysisofimmunologicalmemoryforjohncunninghamvirusinamexicanpopulationofpatientswithmultiplesclerosisundertreatment